HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Philippe Beauchemin Selected Research
Philippe Beauchemin Research Topics
Disease
3
Multiple Sclerosis
02/2024 - 12/2016
2
Infections
02/2024 - 01/2022
1
Chronic Progressive Multiple Sclerosis
02/2024
1
Agammaglobulinemia (Hypogammaglobulinemia)
02/2024
1
Demyelinating Diseases (Demyelinating Disease)
08/2023
1
Leukocytosis (Pleocytosis)
08/2023
1
Disease Progression
08/2023
1
Vitelliform Macular Dystrophy
08/2023
1
Guillain-Barre Syndrome
06/2022
1
Vasculitis (Vasculitides)
06/2022
1
Primary Myelofibrosis (Myelosclerosis)
06/2022
1
Relapsing-Remitting Multiple Sclerosis
06/2022
1
Autoimmune Diseases (Autoimmune Disease)
06/2022
1
COVID-19
01/2022
1
Brain Diseases (Brain Disorder)
01/2022
1
Neuromyelitis Optica (Devic's Disease)
12/2016
1
Rheumatoid Arthritis
02/2016
Drug/Important Bio-Agent (IBA)
2
tocilizumab (atlizumab)
FDA Link
12/2016 - 02/2016
1
ocrelizumab
IBA
02/2024
1
Immunoglobulin A (IgA)
IBA
02/2024
1
Immunoglobulin M (IgM)
IBA
02/2024
1
Immunoglobulin G (IgG)
IBA
02/2024
1
Myelin-Oligodendrocyte Glycoprotein
IBA
08/2023
1
Oligoclonal Bands
IBA
08/2023
1
2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)
IBA
12/2022
1
Alemtuzumab (Campath)
FDA Link
06/2022
1
Vaccines
IBA
01/2022
1
COVID-19 Vaccines
IBA
01/2022
Therapy/Procedure
3
Therapeutics
02/2024 - 02/2016